All In Biotech

Drug Trial Radar · NCT04928144

Phase 1 Study of SHJ002 Sterile Ophthalmic Solution in Pediatric Subjects

An Intra-subject Dose Escalation Phase 1 Study to Determine the Safety and Tolerability of SHJ002 Sterile Ophthalmic Solution in Pediatric Subjects

Last checked: Nov 19, 2026Latest source record: Mar 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Jul 2, 2021

Primary completion

Sep 17, 2021

Study completion Sep 17, 2021

Sponsor

Lead sponsor
Sunhawk Vision Biotech, Inc.Industry
Sponsor type
Industry
First posted
Jun 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 10 years, up to 15 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, open-label, first-in-human dose-escalation study of SHJ002 Ophthalmic Solution in children. (Part 1) Three (3) subjects will receive each concentration of SHJ002 for 3 days in an escalation design in one eye. (Part 2) A Group of 9 additional children will receive the highest tolerated concentration for 28 days.

Conditions

  • Myopia

Interventions

  • SHJ - Low concentrationDrug

    Topical ophthalmic

  • SHJ - Mid concentrationDrug

    Topical ophthalmic

  • SHJ - High concentrationDrug

    Topical ophthalmic

  • SHJ - Maximum toleratedDrug

    SHJ - Maximum tolerated

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in best corrected visual acuityTime frame: 3 days (Part 1) and 28 days (Part 2)
  2. Incidence of Adverse EventsTime frame: 3 days (Part 1) and 28 days (Part 2)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kaohsiung Veterans General Hospital

    Kaohsiung City, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.